- Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients
- The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors
- Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful
- Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023
In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology, achieved several important goals for the year, according to CEO Chris Bunka.
“One of our biggest achievements of 2022 was our greater emphasis on commercial pursuits,” Bunka wrote in his January 2023 letter to shareholders (https://ibn.fm/SPqK7). This saw the company acquire new customers, among them Premier Wellness Science Co. Ltd. of Japan, its first client in Asia, BevNology LLC (https://ibn.fm/JWAlF), and AnodGen Bioceuticals (https://ibn.fm/DNZ3q).
This year, the company is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its DehydraTECH technology for both consumer and pharmaceutical sectors. And while Lexaria is not at liberty to go into details, its approach to commercialization has been strategic.
Strategic partnerships involving small to mid-sized biotech as well as large pharmaceutical companies are not new. As reported in a recent article in LabioTech, such partnerships are a better way to build a product’s capabilities and value than outright acquisitions (https://ibn.fm/GeSd1). Additionally, these collaborations provide access to Big Pharma’s infrastructure, resources, and expertise, depending on the terms of the agreements, which can substantially reduce risk.
However, the materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, the article observes, “The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in.” Moreover, the clinical development timeframe also matters, with the article noting that “The further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties.”
Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023. The patents cover method-of-use, composition-of-matter and medical treatment claims for a wide range of active pharmaceutical ingredients (“APIs”), including, but not limited to, cannabidiol (“CBD”), antiviral drugs, vitamins, nicotine, and NSAIDs. Additionally, Lexaria has many more patents pending around the world.
Lastly and perhaps most importantly, Lexaria has substantially invested in research and development (“R&D”), an aspect of its operations that is 100% within its control. According to Bunka, the company has designed its applied R&D to boost its commercial prospects, and this “is paying off in spades,” as it has, among others, “yielded almost entirely positive results.”
In 2022, the company’s top priority was to develop its DehydraTECH-processed CBD hypertension program. The program’s fifth and most comprehensive human clinical study, the HYPER-H21-4, has proven a success. Firstly, the study showed that DehydraTECH-CBD was exceptionally safe, had a high tolerability profile, resulted in a statistically significant decrease of 24-hour ambulatory blood pressure (“BP”), and lowered BP throughout the entire 5-week duration of the study (https://ibn.fm/I2Pz0).
Subsequent results showed that DehydraTECH-CBD achieves better human blood absorption levels at lower doses than non-Lexaria CBD formulations (https://ibn.fm/tXWt9). The study also helped Lexaria discover a novel mechanism of action of the DehydraTECH-CBD capsule formulation in reducing BP (https://ibn.fm/NZvgr). Other applied R&D programs include an oral nicotine program, wherein dosing began late last year, and separate studies evaluating the effect of DehydraTECH-CBD on seizure disorders, diabetes, and dementia.
Lexaria continues to develop appeal to potential collaborators, and its R&D serves as evidence of the resolve to attract investments and partnerships from larger companies.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.